Transoral Incisionless Fundoplication in Patients With Barrett's Esophagus

Abstract

During the past several decades, esophageal adenocarcinoma (EAC) has become one of the fastest growing cancers in the Western world, with over a 7-fold increase in incidence.1,2 Barrett's esophagus (BE) is a known precursor of EAC, and the risk of progression from BE to EAC correlates with the degree of dysplasia.3-5 Thus, early detection and treatment of dysplastic BE is paramount for prevention of EAC. The current standard of care for treatment of dysplastic BE is endoscopic eradication therapy (EET) with endoscopic mucosal resection of visible lesions followed by ablative therapy for remaining flat BE.